活动性狼疮肾炎患者对拮抗性抗CD40抗体BI 655064的临床与生物标志物应答:一项随机、双盲、安慰剂对照II期试验
121例活动性狼疮肾炎患者按2:1:1:2随机接受安慰剂或BI 655064 120、180、240 mg,在霉酚酸酯和糖皮质激素基础上加用。第52周完全肾脏缓解(CRR)未显示剂量-反应关系(120 mg 38.3%、180 mg 45.0%、240 mg 44.6%、安慰剂48.3%)。事后分析提示BI 655064 180 mg可能获益。
要点
- 第52周CRR未显示剂量-反应关系:120 mg 38.3%、180 mg 45.0%、240 mg 44.6%、安慰剂48.3%。
- 事后分析确认CRR:120 mg 22.5%、180 mg 44.3%、240 mg 38.2%、安慰剂29.1%。
- 240 mg组严重感染率10%高于其他组4.8-5.0%,严重不良事件率20%高于其他组7.5-10%。
核心结论
- 试验未能证明主要CRR终点的剂量-反应关系。
- 事后分析提示BI 655064 180 mg在活动性狼疮肾炎患者中可能有潜在获益。
研究设计与样本
- 随机、双盲、安慰剂对照II期试验,共121例活动性狼疮肾炎患者按2:1:1:2随机接受安慰剂或BI 655064 120、180、240 mg。
- BI 655064在霉酚酸酯和糖皮质激素基础上加用,先每周负荷剂量共3周,随后120和180 mg组每2周给药,240 mg组每周120 mg给药。
- 主要终点为第52周完全肾脏缓解(CRR),次要终点包括第26周CRR。
主要发现
- 第52周CRR:BI 655064 120 mg组38.3%、180 mg组45.0%、240 mg组44.6%、安慰剂组48.3%,未显示剂量-反应关系。
- 第26周CRR:120 mg组28.6%、180 mg组50.0%、240 mg组35.0%、安慰剂组37.5%。
- 事后分析确认CRR(第46和52周):120 mg组22.5%、180 mg组44.3%、240 mg组38.2%、安慰剂组29.1%。
- 大多数患者报告至少1次不良事件:BI 655064组85.7-95.0%,安慰剂组97.5%,最常见为感染和侵染(BI 655064组61.9-75.0%,安慰剂组60%)。
- 与其他组相比,240 mg BI 655064组报告更高的严重不良事件率(20% vs 7.5-10%)和严重感染率(10% vs 4.8-5.0%)。
关键数值与推荐
- 主要终点第52周CRR未显示剂量-反应关系:120 mg 38.3%、180 mg 45.0%、240 mg 44.6%、安慰剂48.3%。
- 事后分析cCRR:120 mg 22.5%、180 mg 44.3%、240 mg 38.2%、安慰剂29.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as an add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN). METHODS: A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 655064 120, 180, or 240 mg and received a weekly loading dose for 3 weeks followed by dosing every 2 weeks for the 120 and 180 mg groups, and 120 mg weekly for the 240 mg group. The primary endpoint was complete renal response (CRR) at week 52. Secondary endpoints included CRR at week 26. RESULTS: A dose-response relationship with CRR at week 52 was not shown (BI 655064 120 mg, 38.3%; 180 mg, 45.0%; 240 mg, 44.6%; placebo, 48.3%). At week 26, 28.6% (120 mg), 50.0% (180 mg), 35.0% (240 mg), and 37.5% (placebo) achieved CRR. The unexpected high placebo response prompted a post hoc analysis evaluating confirmed CRR (cCRR, at weeks 46 and 52). cCRR was achieved in 22.5% (120 mg), 44.3% (180 mg), 38.2% (240 mg), and 29.1% (placebo) of patients. Most patients reported ≥1 adverse event (BI 655064, 85.7-95.0%; placebo, 97.5%), most frequently infections and infestations (BI 655064 61.9-75.0%; placebo 60%). Compared with other groups, higher rates of serious (20% vs. 7.5-10%) and severe infections (10% vs. 4.8-5.0%) were reported with 240 mg BI 655064. CONCLUSION: The trial failed to demonstrate a dose-response relationship for the primary CRR endpoint. Post hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.
引用
- Jayne DR, Steffgen J, Romero-Diaz J, et al. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Arthritis Rheumatol. 2023. PMID: 37192040. doi:10.1002/art.42557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。